botensilimab,balstilimab
agenus
 more details below:
- orr 24%, and dcr of 73%, in heavily pre-treated patients with a median of 4 prior lines of therapy
- responses to botensilimab/balstilimab were durable, with 80% ongoing at data cut-off and median duration of response not reached
he for she. GI Oncologist@Milwaukee, alum of #AIIMS (New Delhi), #NIH and #MayoClinic. Focus- #CRC, #UGI cancers, biliary cancer